Dare Bioscience Inc (DARE) Stock Price, Quote & News

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 926 7655

Website: darebioscience.com

Address:

3655 Nobel Drive, Suite 260, San Diego, United States

TravisA9 Aug. 19 at 5:14 PM

$DARE

0 · Reply

Mike_Rotsch Aug. 19 at 2:30 PM

$DARE I'm in.

1 · Reply

HMIC Aug. 19 at 1:58 PM

$DARE

0 · Reply

Teddy313 Aug. 18 at 9:47 PM

$DARE At this price with all that’s going on with the company it’s like buying a lottery ticket but with much better odds of winning. I’m loaded and holding for the payoff.

0 · Reply

jpoptions Aug. 18 at 6:47 PM

$DARE Holding. Think and hope .75cents is the low. GLTA

0 · Reply

Delthefunkeehomosapian Aug. 18 at 6:39 PM

$DARE Have my order open for a 1,500 at .73. I'll buy another round if we dip lower.

0 · Reply

HMIC Aug. 18 at 4:50 PM

$DARE

3 · Reply

Mattgama1 Aug. 18 at 2:31 PM

$DARE At this rate, the offering won’t close until sometime next week

1 · Reply

ShangVXO Aug. 18 at 2:30 PM

$DARE this is kinda too interesting to ignore

1 · Reply

WeBeSeeingGreen Aug. 17 at 7:52 PM

$DARE I am glad I had little to no faith in this, however at these prices it’s looking inviting.. or stupid? Thoughts?

1 · Reply

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

2026-08-16T12:52:02.000Z - 3 days ago

Dare Bioscience announces pricing of $6M registered direct offering

Aug 14, 2026, 12:45 PM EDT - 5 days ago

Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aug 13, 2026, 4:30 PM EDT - 5 days ago

Daré Bioscience Earnings Call Transcript: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

Daré Bioscience Quarterly report: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

Daré Bioscience Earnings release: Q2 2026

Aug 13, 2026, 4:01 PM EDT - 5 days ago

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances

Aug 6, 2026, 9:05 AM EDT - 13 days ago

Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026

Jul 28, 2026, 8:34 AM EDT - 22 days ago

Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx

Jul 20, 2026, 9:01 AM EDT - 4 weeks ago

Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities

Jul 14, 2026, 4:00 PM EDT - 5 weeks ago

Daré Bioscience Transcript: Virtual Investor Closing Bell

Jul 9, 2026, 8:43 AM EDT - 5 weeks ago

Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event

Jul 1, 2026, 8:55 AM EDT - 7 weeks ago

Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform

Jun 25, 2026, 9:05 AM EDT - 7 weeks ago

Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

Jun 18, 2026, 9:20 AM EDT - 2 months ago

Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026

Jun 11, 2026, 12:00 PM EDT - 2 months ago

Daré Bioscience Transcript: AGM 2026

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Daré Bioscience Proxy statement: Proxy filing

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Daré Bioscience Proxy statement: Proxy filing

2026-05-26T12:19:36.000Z - 3 months ago

Dare Bioscience receives NIH funding award notice to advance DARE-HPV

May 26, 2026, 8:00 AM EDT - 3 months ago

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

2026-05-18T12:14:40.000Z - 3 months ago

Dare Bioscience initiates DARE-HPV clinical study

May 18, 2026, 8:00 AM EDT - 3 months ago

Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

May 14, 2026, 4:30 PM EDT - 3 months ago

Daré Bioscience Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Daré Bioscience Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Daré Bioscience Earnings release: Q1 2026

May 14, 2026, 4:01 PM EDT - 3 months ago

Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-12T19:41:03.000Z - 3 months ago

Dare Bioscience reports positive interim Phase 3 results for Ovaprene

May 12, 2026, 8:00 AM EDT - 3 months ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

May 7, 2026, 8:00 AM EDT - 3 months ago

Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Daré Bioscience Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Daré Bioscience Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Daré Bioscience Proxy statement: Proxy filing

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Daré Bioscience Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Daré Bioscience Annual report: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Daré Bioscience Earnings release: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Daré Bioscience Slides: Q4 2025

Mar 26, 2026, 4:01 PM EDT - 5 months ago

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

Mar 23, 2026, 8:00 AM EDT - 5 months ago

On National Viagra Day, Women Finally Claim Their Turn:

2026-03-16T12:39:51.000Z - 5 months ago

Dare Bioscience receives NIH funding award notice for DARE-PTB1

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Mar 2, 2026, 1:40 PM EST - 6 months ago

Daré Bioscience Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-23T13:22:55.000Z - 6 months ago

Dare Bioscience announces FDA clearance of IND application for Dare-HPV

Feb 23, 2026, 8:00 AM EST - 6 months ago

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

2026-02-11T13:23:08.000Z - 6 months ago

Dare announces availability of telehealth consultations for DARE to PLAY

2025-12-10T13:10:49.000Z - 9 months ago

Dare Bioscience announces providers in select states can prescribe DARE to PLAY

Dec 10, 2025, 8:00 AM EST - 9 months ago

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

2025-12-01T13:20:39.000Z - 9 months ago

Dare Bioscience announces return of rights to Oveprene

2025-11-24T13:30:31.000Z - 9 months ago

Dare Bioscience receives $3.6M in additional grant funding

Nov 13, 2025, 4:30 PM EST - 9 months ago

Daré Bioscience Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Daré Bioscience Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Daré Bioscience Earnings release: Q3 2025

Nov 13, 2025, 4:01 PM EST - 9 months ago

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2025-11-11T13:10:31.000Z - 10 months ago

Dare Bioscience to host webinar on the DARE to PLAY

Nov 6, 2025, 8:00 AM EST - 10 months ago

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

2025-11-03T13:20:56.000Z - 10 months ago

Dare Bioscience to receive up to $300,000 to conduct landscape review

2025-10-06T12:20:36.000Z - 11 months ago

Dare Bioscience receives $4M non-dilutive grant installment

2025-09-24T12:11:38.000Z - 11 months ago

Dare Bioscience to receive up to $499,000 to support preeclampsia research

Sep 24, 2025, 8:00 AM EDT - 11 months ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

2025-09-04T11:45:08.000Z - 1 year ago

Dare Bioscience upgraded to Buy from Hold at Maxim

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings release: Q2 2025

Aug 14, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

2025-07-29T12:21:48.000Z - 1 year ago

Dare Bioscience, Rosy Wellness launch first phase to support DARE to PLAY

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 21, 2025, 1:47 PM EDT - 1 year ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

2025-07-21T12:27:31.000Z - 1 year ago

Dare Bioscience to host webinar on Sildenafil cream

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jun 12, 2025, 5:00 PM EDT - 1 year ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Proxy statement: Proxy Filing

Jun 9, 2025, 7:00 AM EDT - 1 year ago

Daré Bioscience Slides: Corporate Presentation

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings release: Q1 2025

May 13, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Proxy statement: Proxy Filing

Apr 9, 2025, 4:00 PM EDT - 1 year ago

Daré Bioscience Transcript: Jones Healthcare and Technology Innovation Conference 2025

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Annual report: Q4 2024

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Feb 6, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Jan 9, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 15, 2024, 7:00 AM EST - 1 year ago

Daré Bioscience Registration statement: Registration Filing

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Earnings Call Transcript: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Earnings release: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Quarterly report: Q3 2024

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Quarterly report: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings release: Q2 2024

Aug 12, 2024, 4:01 PM EDT - 2 years ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Jul 19, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 1, 2024, 6:54 AM EDT - 2 years ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Reverse Stock Split

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings release: Q1 2024

May 14, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 2, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Registration statement: Registration Filing

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Registration statement: Registration Filing

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Annual report: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings release: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

TravisA9 Aug. 19 at 5:14 PM

$DARE

0 · Reply

Mike_Rotsch Aug. 19 at 2:30 PM

$DARE I'm in.

1 · Reply

HMIC Aug. 19 at 1:58 PM

$DARE

0 · Reply

Teddy313 Aug. 18 at 9:47 PM

$DARE At this price with all that’s going on with the company it’s like buying a lottery ticket but with much better odds of winning. I’m loaded and holding for the payoff.

0 · Reply

jpoptions Aug. 18 at 6:47 PM

$DARE Holding. Think and hope .75cents is the low. GLTA

0 · Reply

Delthefunkeehomosapian Aug. 18 at 6:39 PM

$DARE Have my order open for a 1,500 at .73. I'll buy another round if we dip lower.

0 · Reply

HMIC Aug. 18 at 4:50 PM

$DARE

3 · Reply

Mattgama1 Aug. 18 at 2:31 PM

$DARE At this rate, the offering won’t close until sometime next week

1 · Reply

ShangVXO Aug. 18 at 2:30 PM

$DARE this is kinda too interesting to ignore

1 · Reply

WeBeSeeingGreen Aug. 17 at 7:52 PM

$DARE I am glad I had little to no faith in this, however at these prices it’s looking inviting.. or stupid? Thoughts?

1 · Reply

PoorOffTrading Aug. 17 at 2:16 PM

$DARE Jumping in tomorrow, regardless. This will touch -9% today at a minimum, then do a -3%, before a swing up.

2 · Reply

RunningRobert1 Aug. 17 at 1:27 PM

$DARE Dare Bioscience DARE Q2 2026 Summary 17Aug2026 https://youtu.be/BntImkj-dbg Well that was unexpected, mid Friday afternoon dilution arent really a thing! Overall its going to be how the launches go, and getting though 2027 to get both data readouts, so we will see!

0 · Reply

focafoca99 Aug. 17 at 1:17 PM

$DARE conducted a $6M financing, issuing 4.1M shares, pre-funded and Series A/B warrants under a securities purchase agreement. https://www.rapidticker.com/news/dare-sec-filing-25dca3

0 · Reply

StockJayC Aug. 17 at 11:58 AM

$DARE Christ, used to invest in this a few years ago, held and sold for a small gain. Not a fan of the CEO at all, think Sabrina is incompetant and not ready for the role. Price is looking super attractive but is the company ready to transition??? Will be entering back in soon but holding off at the moment. Nice to see some old faces and Jedi still holding down the fort!

0 · Reply

supersox Aug. 16 at 6:12 PM

$DARE Interesting

0 · Reply

HMIC Aug. 16 at 12:21 PM

$DARE

0 · Reply

Teddy313 Aug. 15 at 4:24 PM

$DARE When everyone is crying I’m buying and it worked many times. DARÉ has Bottomed IMO.

2 · Reply

lnfr Aug. 15 at 4:09 PM

$DARE hoping this snaps back to over a dollar after offering shock

0 · Reply

Donniechen12345 Aug. 15 at 2:40 PM

$DARE lmao scammed investors $8.8 millions on a 15mil micro market cap hahahaha …… i guaranteed 110% like all scam micro cap stocks that it WILL keep dropping all month to .20-.30 cents soon …… you BETTER fking stay away from these trash scam ponzi schme stocks and DONT be forever dumb and stupid smh …. and please fall for all those FAKE bullish spammers telling you bullish buy and buy SMH. please be dont an diot , only the pro knows hehe , rookies will get served lol

1 · Reply

BiotechJedi1728 Aug. 15 at 1:16 AM

$DARE At this point I might as well double down again. That would get my average to 1.2. Thank god only 100s of shares instead of the thousands I used to have and sold. Year of the investors! 🙄

1 · Reply

HMIC Aug. 15 at 1:10 AM

$DARE offering issued at $1.37, my average .88 .

1 · Reply

jpoptions Aug. 14 at 9:36 PM

$DARE @DARE - warrants subject to shareholder approval. Contact your large shareholders to discuss.

0 · Reply

Market Cap	12.22M
Revenue (ttm)	1.03M
Net Income (ttm)	-13.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,300.97%
Debt to Equity Ratio	0.00

Volume	483,485
Avg Vol	501,382
Day's Range	N/A - N/A
Shares Out	15.08M
Stochastic %K	2%
Beta	1.08
Analysts	Strong Sell
Price Target	$9.67